Inthera Bioscience

About us

The management of Inthera Bioscience AG has more that 100 years of combined experience within biotech/pharma industry. Their expertise covers the entire value chain from target discovery and validation to early drug discovery, medicinal chemistry, pre-clinical and toxicology works as well as early clinical development. Furthermore the team has substantial experience in business development, deal transactions in general and in people management.

Board of Directors

Anker Lundemose
CEO Mission Therapeutics 

Roland Walder
Formerly Steiner AG, Jelmoli  

Mark Krul
Aglaia Oncology Funds

Emmanuelle Coutanceau
Novo Holdings 

Christian Uhrich
M Ventures

Main Shareholders